Vanda Pharmaceuticals (NASDAQ:VNDA) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report issued on Wednesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald lifted their price target on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a report on Thursday, August 1st.

Vanda Pharmaceuticals Stock Up 3.7 %

Shares of NASDAQ VNDA opened at $4.91 on Wednesday. The stock has a market capitalization of $285.75 million, a P/E ratio of -61.38 and a beta of 0.77. The stock’s 50 day moving average price is $4.95 and its two-hundred day moving average price is $5.23. Vanda Pharmaceuticals has a 52-week low of $3.30 and a 52-week high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $50.47 million for the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. On average, analysts anticipate that Vanda Pharmaceuticals will post -0.49 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC increased its position in Vanda Pharmaceuticals by 4.7% in the first quarter. Acadian Asset Management LLC now owns 2,370,335 shares of the biopharmaceutical company’s stock worth $9,740,000 after buying an additional 107,203 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Vanda Pharmaceuticals by 17.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company’s stock worth $11,379,000 after acquiring an additional 292,172 shares during the period. Nantahala Capital Management LLC lifted its position in Vanda Pharmaceuticals by 57.3% in the 2nd quarter. Nantahala Capital Management LLC now owns 1,593,516 shares of the biopharmaceutical company’s stock valued at $9,003,000 after purchasing an additional 580,265 shares during the last quarter. Profit Investment Management LLC boosted its stake in Vanda Pharmaceuticals by 159.3% during the 2nd quarter. Profit Investment Management LLC now owns 571,324 shares of the biopharmaceutical company’s stock valued at $3,228,000 after purchasing an additional 351,000 shares during the period. Finally, Sei Investments Co. grew its position in Vanda Pharmaceuticals by 39.6% in the 1st quarter. Sei Investments Co. now owns 518,851 shares of the biopharmaceutical company’s stock worth $2,132,000 after purchasing an additional 147,066 shares during the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.